Scandion Oncology AS (OSTO:SCOL) Interest Expense : kr-0.84 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Scandion Oncology AS's interest expense for the three months ended in Dec. 2024 was kr -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.84 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Scandion Oncology AS's Operating Income for the three months ended in Dec. 2024 was kr -21.59 Mil. Scandion Oncology AS's Interest Expense for the three months ended in Dec. 2024 was kr -0.01 Mil. Scandion Oncology AS did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scandion Oncology AS Interest Expense Historical Data

The historical data trend for Scandion Oncology AS's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS Interest Expense Chart

Scandion Oncology AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.06

-1.06

-0.73

-0.06

-0.01

Scandion Oncology AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-0.35	-0.20	-0.08	-0.55	-0.01

Scandion Oncology AS Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.84 Mil.

Scandion Oncology AS (OSTO:SCOL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scandion Oncology AS's Interest Expense for the three months ended in Dec. 2024 was kr-0.01 Mil. Its Operating Income for the three months ended in Dec. 2024 was kr-21.59 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was kr0.00 Mil.

Scandion Oncology AS's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Scandion Oncology AS did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Scandion Oncology AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

8VY:Germany

Address

Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100

Website

https://www.scandiononcology.com

Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options. The company's pipeline includes products like COROST for Colorectal Cancer, PANTAX for Pancreatic Cancer, 101 for other cancer indiction, 201 for Solid Tumors.

Scandion Oncology AS Headlines

No Headlines